For decades, the fight against HIV has been a global challenge. However, a new medical breakthrough could revolutionize prevention of the virus: the drug Lenacapavir , an injection that offers protection against HIV for a full year with a single dose.

This treatment, tested in clinical trials, has demonstrated 100% effectiveness in preventing HIV , making it one of the most promising strategies in the history of medicine.

This medication belongs to a new class of antivirals called HIV capsid inhibitors , which block the virus's ability to replicate within the body. Unlike current treatments that require daily pills, Lenacapavir only needs to be administered once a year , making it easier to adhere to treatment and reducing the chance of missing doses.

Despite its effectiveness, the distribution of Lenacapavir faces a major challenge: its high price. Currently, each dose costs around $20,000 , making it inaccessible to millions of people at risk.

Health organizations have called on manufacturers to lower the price of Lenacapavir and work in partnership with governments and NGOs to ensure access in countries with high HIV rates. If this is achieved, Lenacapavir could be key to drastically reducing annual infections , which currently number 1.3 million new cases worldwide .

While an HIV vaccine is not yet a reality, advances like this bring humanity closer to a future without new infections. The key will be making this treatment accessible to everyone, especially in vulnerable communities.